AniLocus Outstanding Preclinical CRO Services
Preclinical In Vivo Research Solutions | Biopharma CRO Contact Us!
AniLocus | Preclinical CRO | Dermatology, Skin Diseases, Acne, Connective Tissue, Wound Healing
Preclinical CRO Services

Speak with a Scientist Today!

Schedule a consult today and let's discuss how AniLocus can advance your product from Bench-to-Market.

In the United States, nearly 85 million people are diagnosed with a skin disorder. The most diagnosed skin diseases include fungal skin infections, acne, dandruff, dermatitis, eczema, alopecia, and skin pigment disorders.

AniLocus partners with companies developing therapeutics for skin disorders therapeutics to utilize relevant, translational models for dermatology drug and device development.

AniLocus Services for Dermatology Drug Development

We utilize ex vivo and in vivo models for skin and connective tissue diseases including:

  • Acne
  • Albinism
  • Alopecia
  • Collagen diseases
  • Connective tissue diseases
  • Dermatitis
  • Eczematous
  • Hair Diseases
  • Neoplasms
  • Psoriasis
  • Rare Genetic Skin Diseases
  • Rheumatic Diseases
  • Skin Cancer
  • Skin Infections
  • Skin Inflammation
  • Skin Microbiome
  • Skin Pigment Disorders (Hypopigmentation/Hyperpigmentation)
  • Ulcerations
  • Vitiligo
  • Wound Healing

AniLocus Services for Dermatology Medical Devices

We also conduct preclinical toxicology studies to assess medical devices with adhesion for topical and transdermal delivery systems (TDS). We can assist in studies that thoroughly test drug safety, efficiency, efficacy, and consistency.

Multiple animal models are used in preclinical product development including:

  • Gene knockout/knockin/trapped
  • Transgenic rodents
  • Chemically-Induced Point Mutation rodents
  • Stress-induced models
  • Drug-Induced models
  • Wound/Laceration Models
  • Metabolically-induced models (Diet-induced, Metabolic disorder, micronutrient deficient)
  • And more…

We conduct translational animal studies (in vivo and in vitro) collecting detailed, comprehensive results with rapid turnaround.

Drug modalities are different types of therapeutic agents. Each drug is a customizable tool designed for therapeutic intervention. The question is…does your product work and is it safe?

At AniLocus, we conduct relevant preclinical studies to assess any drug modality:

  • Antibodies (nanobodies, monoclonal)
  • Gene therapy (CRISPR, TALEN)
  • Viral therapy (adenovirus-AAV, lentivirus)
  • Oligo- and polypeptides (e.g., stapled and modified peptides)
  • Oligo- and polynucleotides (e.g., siRNAs, mRNAs, aptamers)
  • Polyglycosides
  • Macrocyclic molecules
  • Drug conjugates (e.g., antibody–drug conjugates, drug–drug conjugates, fluorescence-labeled drugs)
  • Targeted protein degraders (e.g., proteolysis-targeting chimeras (PROTACs) and molecular glues) that induce a chemical knockdown of proteins
  • Cellular therapies (stem cells, allogenic, autologous)

Using animal and human cells and tissue we can perform multiple interrogative assays depending on therapeutic area and sample type:

  • DNA: Extraction, PCR, ddPCR, qPCR, sequencing, genotyping
  • RNA: Gene expression profiling, RT-PCR, miRNA, Next-generation sequencing (Nanostring, Illumina), spatial transcriptomics, In situ hybridization (ISH), Multiplex ISH
  • Protein: Immunoassays (ELISA, EIA, Luminex), proteomics, ligand binding assays, protein expression, immunohistochemistry (IHC), immunocytochemistry (ICC), and  immunofluorescence (IF)
  • And more!
  1. Karimkhani C, Dellavalle RP, Coffeng LE, et al. Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatol. 2017;153(5):406–412. doi:10.1001/jamadermatol.2016.5538. < https://jamanetwork.com/journals/jamadermatology/fullarticle/2604831 >.
  2. Therdpong Tempark, Khwaunrat Whaidee, Chansuda Bongsebandhu-phubhakdi, Orapa Suteerojntrakool, Prevalence of skin diseases in school-age children, Family Practice, Volume 39, Issue 3, June 2022, Pages 340–345. < https://doi.org/10.1093/fampra/cmab164 >.
  3. Svensson, A., Ofenloch, R. F., Bruze, M., Naldi, L., Cazzaniga, S., Elsner, P., Goncalo, M., Schuttelaar, M. A., & Diepgen, T. L. (2018). Prevalence of skin disease in a population-based sample of adults from five European countries. The British journal of dermatology, 178(5), 1111–1118. < https://doi.org/10.1111/bjd.16248 >.
  4. Wang, C., Strasinger, C., Shen, M., & Tsong, Y. (2020). Statistical Considerations in Assessing In Vivo Adhesion with Transdermal and Topical Delivery Systems for New Drug Applications. The AAPS journal, 22(6), 137. < https://doi.org/10.1208/s12248-020-00519-z >.
  5. Schön, M. P., Manzke, V., & Erpenbeck, L. (2021). Animal models of psoriasis-highlights and drawbacks. The Journal of allergy and clinical immunology, 147(2), 439–455. < https://doi.org/10.1016/j.jaci.2020.04.034 >.
  6. Lewis, B., & Branch, D. R. (2020). Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Fc Receptor-Targeting Biologics. Pharmacology, 105(11-12), 618–629. < https://doi.org/10.1159/000508239 >.
Need some advice from our experts?

Contact Us!

Send us a message or schedule a consultation today.

Together, we will discuss your research needs and generate a preclinical service proposal for your immediate review.